Synagis
Synagis (palivizumab) is a humanized monoclonal antibody directed against the F glycoprotein of respiratory syncytial virus (RSV), providing passive immunity to prevent severe RSV infection in high-risk infants.
Dosage by Body Weight
The recommended dose of Synagis is 15 mg/kg of body weight, administered once monthly intramuscularly (IM), preferably in the anterolateral aspect of the thigh, throughout the RSV season (typically 5 monthly doses). Injection volumes greater than 1 mL should be given as divided doses.
- Body Weight
- Below 5 kg
- Dose
- 15 mg/kg (up to 75 mg)
- Frequency
- Once monthly during RSV season
- Tracking Notes
- Administered intramuscularly. Typically given in the anterolateral thigh.
- Body Weight
- 5-7 kg
- Dose
- 75 mg to 105 mg (15 mg/kg)
- Frequency
- Once monthly during RSV season
- Tracking Notes
- Volumes greater than 1 mL should be administered as divided doses.
- Body Weight
- 8-10 kg
- Dose
- 120 mg to 150 mg (15 mg/kg)
- Frequency
- Once monthly during RSV season
- Tracking Notes
- Volumes greater than 1 mL must be given in divided doses at different sites.
- Body Weight
- 11-15 kg
- Dose
- 165 mg to 225 mg (15 mg/kg)
- Frequency
- Once monthly during RSV season
- Tracking Notes
- Ensure divided doses are used for injection volumes exceeding 1 mL.
- Body Weight
- 16-20 kg
- Dose
- 240 mg to 300 mg (15 mg/kg)
- Frequency
- Once monthly during RSV season
- Tracking Notes
- Ensure divided doses are used for injection volumes exceeding 1 mL.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | 15 mg/kg (up to 75 mg) | Once monthly during RSV season | Administered intramuscularly. Typically given in the anterolateral thigh. |
| 5-7 kg | 75 mg to 105 mg (15 mg/kg) | Once monthly during RSV season | Volumes greater than 1 mL should be administered as divided doses. |
| 8-10 kg | 120 mg to 150 mg (15 mg/kg) | Once monthly during RSV season | Volumes greater than 1 mL must be given in divided doses at different sites. |
| 11-15 kg | 165 mg to 225 mg (15 mg/kg) | Once monthly during RSV season | Ensure divided doses are used for injection volumes exceeding 1 mL. |
| 16-20 kg | 240 mg to 300 mg (15 mg/kg) | Once monthly during RSV season | Ensure divided doses are used for injection volumes exceeding 1 mL. |
Formulation
Purpose
Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease.
Generic Name
PalivizumabScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.